NCT00113334View on ClinicalTrials.gov

Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Head and Neck Cancer
Interventions
DRUG

ABT-510

100 mg subcutaneously twice daily

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Abbott
All Listed Sponsors
collaborator

Abbott

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00113334 - Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer | Biotech Hunter | Biotech Hunter